Theramex Announces Strategic Partnership with Viramal to Expand Women’s Health Pipeline

18 June 2026 London, UK – Theramex, a leading global specialty pharmaceutical company dedicated exclusively to women’s health, today announced a strategic co-development partnership with UK-based innovative biotech developer Viramal to advance a novel pipeline asset, further reinforcing its commitment to sustainable long-term growth through targeted pipeline expansion.

The collaboration represents a focused investment in Theramex’s mid- to long-term pipeline, supporting its strategy to complement its established commercial portfolio with innovative, differentiated assets. The partnership highlights Theramex’s disciplined approach to business development, leveraging external innovation to drive value creation while maintaining a clear focus on areas of high unmet need within women’s health.

By combining Viramal’s strong development capabilities and its patented FemMedTech™ platform with Theramex’s global commercial platform and deep category expertise, the partnership is expected to accelerate asset progression and optimise future market potential. This approach aligns with Theramex’s broader objective of building a capital-efficient, scalable pipeline to support sustained revenue growth.

Rob Stewart, Chief Executive Officer of Theramex, commented:

“Theramex is committed to building a robust pipeline of earlier-stage assets in women’s health and ensuring we can offer a broad range of options to women at every stage of their lives alongside our strong existing portfolio. We are excited to partner with Viramal on this program and look forward to collaborating closely to advance this important opportunity”.

Oliver Bates, Chief Executive Officer of Viramal, added:

“We are pleased to partner with Theramex, a leading global women’s health company with a strong commercial presence and proven track record of execution. This collaboration underscores Viramal’s strategic development capabilities and validates the strength and versatility of our patented FemMedTech™ platform in addressing areas of significant unmet medical need.

Theramex’s deep market expertise, established commercial infrastructure, and experienced leadership team make them an ideal partner to advance this programme and maximise its value. Together, we are well positioned to accelerate development and unlock the full potential of this opportunity for patients and stakeholders alike.

This partnership further expands Viramal’s growing portfolio of strategic collaborations and reinforces our ability to attract high-quality partners across multiple therapeutic areas.”

Financial terms of the agreement were not disclosed.

About Theramex

Theramex is a leading global specialty pharmaceutical company dedicated to women and their health. Theramex supports women of all ages by providing a broad portfolio of innovative and established brands covering contraception, fertility, menopause, and osteoporosis. Theramex’s vision is to be a lifetime partner for women and the healthcare professionals who treat them, and is committed to listening to and understanding its patients, serving their needs, and offering effective healthcare solutions that care for and support women through different stages of their lives.

For further information about Theramex, please contact:
info@theramex.com

About Viramal

Viramal is a specialist research and development pharma company based in the UK, with a subsidiary in Sweden developing a portfolio of transformative healthcare products with an innovative, holistic approach to women’s wellbeing. Viramal is working in partnership with a range of global developers to realise its pipeline potential and to address the inequalities in the women’s healthcare market.

Viramal contact: info@viramal.com